AGIO Chief Medical Officer Sarah Gheuens Sells $56K of Stock

Agios Pharmaceuticals, Inc. (NasdaqGS: AGIO) Chief Medical Officer Sarah Gheuens sold 1,489 shares of the company on October 21, 2026, according to a Form 4 filed with the SEC.

AGIO Agios Pharmaceuticals, Inc.

$37 ▲ +36.13% year to date

1M 3M YTD

Daily close · Oct 23, 2026

Inside Sarah Gheuens's Agios Pharmaceuticals Trade

Under a pre-arranged Rule 10b5-1 trading plan, Gheuens sold the shares at a price of $37.53 each, bringing the total value of the transaction to $55,882.17. Following this planned sale, she directly owns 54,645 shares of the biotechnology firm. This transaction reduced her holdings by 2.65%. The stock closed at $37.18 on the day of the trade.

Other Institutional Activity in Agios Pharmaceuticals

Farallon Capital Management LLC grew its holdings by 233,604 shares, ending with 5,917,400 shares worth about $218,943,800. Lynx1 Capital Management Lp added 797,325 shares for a total of 3,408,937 shares valued at roughly $126,130,669. Shaw D.E. & Co., Inc. lifted its stake by 425,779 shares to reach 3,107,005 shares worth about $114,959,185. Conversely, Armistice Capital, LLC trimmed its position by 315,854 shares to hold 2,400,000 shares valued at $88,800,000. Erste Asset Management GmbH reduced its stake by 549,882 shares, finishing with 2,154,900 shares worth roughly $79,731,300.

Agios Pharmaceuticals, Inc. Stock Down 0.5%

Shares recently traded around $37.00 as of October 23, 2026, down slightly from an event-day close of $37.18. The stock trades above both its 50-day moving average of $33.34 and its 200-day moving average of $31.46. The share price sits below its 52-week high of $46.00 and well above its 52-week low of $22.24.

Recent Earnings

For its trailing twelve months, the company generated $98,338,000 in revenue alongside a trailing twelve month earnings per share of -$7.01. The firm posted a year-over-year revenue growth rate of 259.3% and a return on equity of -34.3%. The company's next financial results are scheduled for release on November 5, 2026.

Insider Buying and Selling at Agios Pharmaceuticals, Inc.

Earlier on June 18, 2026, Chief Medical Officer Sarah Gheuens picked up 3,000 shares in an open-market purchase. On the same date, Rahul Ballal acquired 14,950 shares, Jay Backstrom bought 14,950 shares, and Cynthia Smith picked up 2,816 shares.

Analysts Set New Price Targets

On July 31, 2026, Citigroup maintained a buy rating and raised its target to $52.00 from $46.00. On the same day, Truist Securities maintained a buy rating while lowering its target from $41.00 to $39.00. JP Morgan maintained a neutral rating on August 7, 2026, and raised its target to $34.00 from $31.00. On September 21, 2026, B of A Securities maintained a buy rating and raised its target to $50.00 from $46.00. Later, Truist Securities maintained a buy rating on October 7, 2026, with a target of $37.00. Overall, eight analysts track the stock, giving it a consensus buy rating and a mean price target of $45.88.

About Agios Pharmaceuticals, Inc.

Based in Cambridge, Massachusetts, Agios Pharmaceuticals discovers and develops treatments targeting cellular metabolism. The firm focuses primarily on rare genetic diseases, led by its flagship product PYRUKYND for treating hemolytic anemias in adults with pyruvate kinase deficiency.

Bottom Line

Investors will watch the upcoming financial report on November 5, 2026, to gauge operational progress and the commercial uptake of its lead therapy. Monitoring further insider filings can also provide insight into executive positioning.